TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05498259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib 150mg qd PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP-like Regimen
Description: cyclophosphamide, anthracene nucleus chemotherapeutics（doxorubicin，liposomal doxorubicin, etc.）, vinca alkaloids（vincristine, vindesine, etc.），and glucocorticoid （dexamethasone，prednison, etc.）.
Study: NCT05438290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPCP
Description: topical immunomodulator
Study: NCT05535712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Anatomic Resection (Da Vinci SP)
Description: To evaluate the performance and safety of the da Vinci SP® Surgical System in anatomical lung resection
Study: NCT05474560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol (100 mg/day) plus lifestyle intervention
Description: participants accept allopurinol treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg plus lifestyle intervention
Description: participants accept Febuxostat treatment (100 mg, once a day, orally). Behavioral: lifestyle intervention According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life style intervention
Description: According to NAFLD guidelines, participants receive lifestyle intervention (diet and exercise).
Study: NCT04826185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMB-1018972
Description: Modified release (MR) oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching oral tablet
Study: NCT06477315

Intervention type: OTHER
Intervention: survey
Description: telephone surveys
Study: NCT05818631

Intervention type: DIAGNOSTIC_TEST
Intervention: fusion cognitive prostate biopsy
Description: A standard transrectal prostatic biopsy will be performed to both groups. To the group with suspicious lesions in the MRI (PI-RADS 3-5), an added directed cognitive fusion biopsy will be performed.
Study: NCT05935319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vivifrail
Description: Assess the physical activity status of the elderly, use the Vivifrail grade, provide exercise intervention, and improve physical activity function.
Study: NCT06274216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 5000 IU of vitamin D3 orally every day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E 400
Description: 400mg of vitamin E orally every day for 12 weeks
Study: NCT06221605

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The intervention lasted for 6 months and 3 visits (at 0 month, 3rd and 6th month respectively).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: The intervention lasted for 6 months and 3 visits (at 0 month, 3rd and 6th month respectively).
Study: NCT06355960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP Dexmedetomidine
Description: Dexmedetomidine (Precedex) loadings of 1 μg/kg , then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP B
Description: Dexmedetomidine (Precedex) loadings of 0.5 μg/kg , then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP C
Description: Dexmedetomidine (Precedex) loadings of 0.25 μg/kg, then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
Study: NCT05617859

Intervention type: DRUG
Group type: OTHER
Intervention: Lenvatinib mesylate capsule
Description: Lenvatinib mesylate capsule, 8mg (body weight ≤60kg) or 12mg (body weight \>60kg), orally, once daily. Take the medicine about half an hour after meals (the time of taking the medicine should be the same as possible every day) and take it with warm water.
Study: NCT04741685

Intervention type: DEVICE
Intervention: TTSX2
Description: Treatment with Tandem T Slim X2 with Basal IQ

Intervention type: DEVICE
Intervention: MM640G
Description: Treatment with Medtronic Minimed 640G with Smartguard
Study: NCT06271421

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NanoTherm therapy
Description: Cyclic hyperthermia in patients with recurrent glioblastoma multiforme, who underwent implantation of iron oxide nanoparticles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glioma Resection
Description: Removal of brain tumor - gross total ressection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Glioma Resection
Description: Removal of brain tumor - gross total ressection

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy according to Stupp protocol
Description: The total dose according to the Stupp protocol is 60 Gy and is administered in fractions of 2 Gy per day for 5 days (Monday to Friday) for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: chemotherapy according to Stupp protocol
Description: Temozolomide is used during radiotherapy: 75 mg/m2 of body surface area per day for 7 days a week. After the completion of radiotherapy, temozolomide is used as adjuvant therapy - 6 cycles of 150-200 mg/m2 of body surface area for 5 days every 28 days.
Study: NCT05508282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading Bees app and children's book to enhance parent-infant reading quality (0-2 month visit)
Description: The reading intervention will be provided at the baseline clinic well-visit (0-2 months), and is based on the SHARE/STEP approach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading Bees app and children's book to encourage alternatives to digital media (6-month visit)
Description: The digital media (screen time) intervention will be provided at the 6-month clinic well-visit and is based on Baby Unplugged materials (book and app content).
Study: NCT06356376

Intervention type: DEVICE
Intervention: Heat Stimulation
Description: Heat stimulation at a painful, but to the subject tolerable level.
Study: NCT05697484

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: educational game
Description: Control group will be provided with usual care. Intervention group will be provided in addition to the usual care, an access to the mobile game after a simple training for game usage. Both groups will be followed for a period of 3 months.~The mobile game is planned to have the following design:~1. Game will be presented in Arabic language.~2. The game will consist of four levels. a. At the beginning of each level there will be an educational video that the patient must watch in order to be allowed to start the level.
Study: NCT05944770

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DIY portable air cleaner with a highly effective filter
Description: A portable air filtration device that can be homemade (DIY), constructed by attaching a highly effective air filter (MERV13 rating or higher) to a 20 inch box fan to filter air pollutants including particulate matter of size 2.5 micrometers diameter or greater.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: DIY portable air cleaner with sham filtration
Description: A portable air filtration device that can be homemade (DIY) by attaching an air filter to a 20 inch box fan. The portable air cleaner with sham filtration with have a filter that is not effective for filtration of fine particulate matter, including that in wildfire smoke.
Study: NCT05155631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGNITIVE BEHAVIORAL THERAPY
Description: 8-10 week self directed on line CBT program approved by FDA
Study: NCT05537337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Intervention
Description: The multicomponent intervention consists of the following components (already described in the detailed description section):~1. Food labels (with the summary of healthiness of shopping baskets \& targets)~2. Ordering~3. Within Group Healthier Substitution
Study: NCT05260710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine Intervention
Description: Tele-Critical Care: 1) establishing a diagnosis 2) guiding the therapeutic approach and 3) performing clinical follow-up. Physicians will discuss all patients in the unit, bed by bed, evaluating the specific clinical situation of each hospitalized patient, according to the protocol developed by the study.The proposal is to maintain horizontal care (the patient is monitored from the 1st day of hospitalization until discharge) for all patients in the unit.~+~Continuing education activities: video classes and discussions of complex cases.
Study: NCT05881668

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC-EV
Description: 10 E10 MSC-EV particles per 100ml for a single dose. No prior HLA matching between MSC donors and recipients or liver donors
Study: NCT05969067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tunneling Technique during RA SCP
Description: As described in the intervention arm above

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dissection Technique during RA SCP
Description: As described in the intervention arm above
Study: NCT05959850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol
Description: Participants in the study will receive varying doses of ambroxol in solution, 3 times per day. Doses will be increased pending a safety review, up to a maximum of 1260mg/day. Blood tests will be conducted weekly to assess tolerance. Compliance will be monitored by returning used bottles. The study will last 32 weeks, including 24 weeks of drug administration and follow-up visits. After the final follow-up, there will be an end of study safety visit occurring 4 weeks later. The total time of participation will be 32 weeks. This includes a screening visit up to 4 weeks prior to Baseline, then a Baseline visit, followed by 24 weeks of follow-up (3x in clinic follow-up visits). These 24 weeks will be the drug administration period, meaning that the total duration of drug administration is 24 weeks. Following this drug administration and follow-up period, there will be an EoS safety-follow up visit that will occur 4 weeks after the final follow-up visit (28 weeks from baseline).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomised to the control arm will receive a placebo for the duration of the study. The placebo will look and taste like ambroxol, but will have no active ingredient. Participants will not be told which arm they have been randomised to. The placebo will primarily be a glucose solution, however it will also have flavouring (e.g. bitters) and colouring, so as to make it look and taste like ambroxol, to maintain blinding.
Study: NCT05734846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lenses (control fitting approach)
Description: Daily wear multifocal lenses for 1 week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lenses (control fitting approach)
Description: Daily wear multifocal lenses for 1 week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lenses (test fitting approach)
Description: Daily wear multifocal lenses for 1 week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lenses (test fitting approach)
Description: Daily wear multifocal lenses for 1 week
Study: NCT04651452

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Value Affirmation
Description: Participants will complete writing tasks regarding their personal values.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reflective Journaling
Description: Participants will complete writing tasks regarding their least important values and discuss why they may be important to others. They will also describe aspects of daily life.
Study: NCT05573932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leaderboard
Description: De-identified leaderboard showing average durations of exercises completed by all participants in leaderboard group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Take-home packet
Description: Take-home packet of exercises.
Study: NCT05471219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primiparous pregnant women who will undergo vaginal examination by focusing on visual traces
Description: Informed consent was obtained from the mothers to take pictures of newborns who were delivered in the delivery room, routinely cared for, dressed and breastfed by the researcher. A 10-minute visual track was created to be turned into a slide from approximately 70 photos. Vaginal examination was performed between the 4th and 6th minutes while focusing on this visual trace.
Study: NCT05509907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedi@ctivity Analysis and Tracking Mobile Applications and Web Platform
Description: Pedi@ctivity Analysis Mobile Application and than Pedi@ctivity Analysis and Tracking Web Platform synchronized with the Pedi@ctivity Tracking Mobile Application, will be developed. The collected data will be analyzed with statistical methods and models using artificial intelligence algorithms will be created. According to the evaluations, physical activity and exercise videos and programs will be prepared and uploaded to web platform. Programs will include stretching, strengthening, balance, aerobic, calisthenic exercises and aerobic dance. The exercise and physical activity program will also be synchronized with the Pedi@ctivity Tracking Mobile Application and the smart watch. Pedi@ctivity Mobile Applications will provide health parameters from the smart watch, suggestions suitable for the exercise and physical activity program, and motivational feedback. Each adolescent will be included in a 3-month program. After the 3-month all evaluations at the beginning will be repeated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedi@ctivity Analysis and Tracking Mobile Applications and Web Platform
Description: Pedi@ctivity Analysis Mobile Application and than Pedi@ctivity Analysis and Tracking Web Platform synchronized with the Pedi@ctivity Tracking Mobile Application, will be developed. The collected data will be analyzed with statistical methods and models using artificial intelligence algorithms will be created. According to the evaluations, physical activity and exercise videos and programs will be prepared and uploaded to web platform. Programs will include stretching, strengthening, balance, aerobic, calisthenic exercises and aerobic dance. The exercise and physical activity program will also be synchronized with the Pedi@ctivity Tracking Mobile Application and the smart watch. Pedi@ctivity Mobile Applications will provide health parameters from the smart watch, suggestions suitable for the exercise and physical activity program, and motivational feedback. Each adolescent will be included in a 3-month program. After the 3-month all evaluations at the beginning will be repeated.
Study: NCT06399380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual mobilization of the carpal bones.
Description: The mobilization of the carpal bones will be done in the following way: patient in supine position, with elbow flexion of approximately 90º, so that the forearm and wrist are almost vertical. The examiner positions the thumb on the dorsal aspect of the scaphoid and trapezius, and the index finger on the dorsal aspect of the piriformis and hamate. Next, a manual ventral force is applied until the resistance of the wrist tissues is felt for 30 seconds. The technique will be repeated 5 times, with a 10-second rest between each application.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A technique will be performed that will have no effect; the hands will be placed at a point that will not be the carpal tunnel, such as the forearm.
Study: NCT05369897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR training
Description: The intervention group will receive cognitive training through VR headsets three times a week for 12 weeks. The intervention will be delivered in a virtual setting using images and music. The participants will be allowed to select the type of music and virtual environment during the intervention. The intervention will include four modules targeting attention and working memory through immersive VR.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VR activity
Description: High-quality 360º images and videos from natural environments, such as a relaxing mountain environment. The participants in the control group will not receive cognitive training.
Study: NCT04750395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol Solution
Description: Oral transmucosal haloperidol solution 2.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine Tablets
Description: Oral transmucosal olanzapine tablet 5.0mg
Study: NCT05912647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MTM
Description: Participants will receive added medicine management support from a pharmacist. This will involve one 60-minute session with the pharmacist either in-person or over the phone and at least four 30-minute follow-up sessions with the pharmacist over the phone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MTM
Description: Participants will receive added medicine management support from a pharmacist. This will involve one 60-minute session with the pharmacist either in-person or over the phone and at least four 30-minute follow-up sessions with the pharmacist over the phone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW
Description: Participants will receive support from a Community Health Worker (CHW) to address life challenges that might be affecting their health and diabetes and to discuss diabetes beliefs and concerns. This will involve one \~30-minute phone call with the CHW to discuss needs and a 2-hour session with the CHW in-person for a comprehensive assessment. Participants will also receive \~10, 15 to 30-minute calls from the CHW to discuss diabetes beliefs and concerns.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW
Description: Participants will receive support from a Community Health Worker (CHW) to address life challenges that might be affecting their health and diabetes and to discuss diabetes beliefs and concerns. This will involve one \~30-minute phone call with the CHW to discuss needs and a 2-hour session with the CHW in-person for a comprehensive assessment. Participants will also receive \~10, 15 to 30-minute calls from the CHW to discuss diabetes beliefs and concerns.
Study: NCT05976321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-279
Description: TAK-279 capsules.
Study: NCT05020158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Talk Intervention
Description: A psychosocial family-based intervention that is designed to give support to an entire family when a child has life-threatening illness.
Study: NCT06292845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical application of a fluorescent imaging agent
Description: The fluorescent imaging agent will be topically applied only onto the resection planes of the freshly resected tumor specimen.~During incubation and after each washing steps, visible light and fluorescent overlay images will be acquired using a fluorescence sensitive camera system.
Study: NCT04756726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemsidomide
Description: oral cemsidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemsidomide
Description: oral cemsidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemsidomide
Description: oral cemsidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemsidomide
Description: oral cemsidomide
Study: NCT05397600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost Ophthalmic
Description: Eyedrops
Study: NCT05397600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost Ophthalmic
Description: Eyedrops
Study: NCT04756726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: oral dexamethasone \[ ≤75 years old: 40 mg once per week (QW) on days 1, 8, 15, and 22; \>75 Years old: 20 mg QW on days 1, 8, 15, and 22\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: oral dexamethasone \[ ≤75 years old: 40 mg once per week (QW) on days 1, 8, 15, and 22; \>75 Years old: 20 mg QW on days 1, 8, 15, and 22\]
Study: NCT06058468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioneuroablation of right anterior ganglionated plexus
Description: Right anterior ganglionated plexus will be localized using anatomical approach. Radiofrequency energy will be delivered until heart rate acceleration \>30% is achieved or if radiofrequency time exceeds 120 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: Application sites near the ostia of pulmonary veins will be determined. Radiofrequency energy will be delivered using point-by-point technique. After applications, the acute PVI endpoint will be confirmed by the elimination of PV potentials and lack of capture during pacing from the ablation lines.
Study: NCT06246851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG Danish
Description: BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
Study: NCT05244824

Intervention type: OTHER
Intervention: Adaptation into Turkish, Examining The Reliability and Validity for People with RA
Description: Adaptation of Evaluation of Daily Activity Questionnaire into Turkish, examining the reliability and validity for people with rheumatoid arthritis